- Home
- AUTL vs PCRX Comparison
AUTL vs PCRX Comparison
Compare AUTL & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- PCRX
- Stock Information
- Founded
- AUTL 2014
- PCRX 2006
- Country
- AUTL United Kingdom
- PCRX United States
- Employees
- AUTL N/A
- PCRX N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- AUTL Health Care
- PCRX Health Care
- Exchange
- AUTL Nasdaq
- PCRX Nasdaq
- Market Cap
- AUTL 590.8M
- PCRX 1.2B
- IPO Year
- AUTL 2018
- PCRX 2011
- Fundamental
- Price
- AUTL $2.17
- PCRX $26.80
- Analyst Decision
- AUTL Strong Buy
- PCRX Buy
- Analyst Count
- AUTL 3
- PCRX 10
- Target Price
- AUTL $10.20
- PCRX $29.30
- AVG Volume (30 Days)
- AUTL 1.1M
- PCRX 892.8K
- Earning Date
- AUTL 03-13-2025
- PCRX 02-27-2025
- Dividend Yield
- AUTL N/A
- PCRX N/A
- EPS Growth
- AUTL N/A
- PCRX N/A
- EPS
- AUTL N/A
- PCRX N/A
- Revenue
- AUTL $10,091,000.00
- PCRX $694,957,000.00
- Revenue This Year
- AUTL $851.83
- PCRX $5.14
- Revenue Next Year
- AUTL $224.65
- PCRX $2.44
- P/E Ratio
- AUTL N/A
- PCRX N/A
- Revenue Growth
- AUTL 82.71
- PCRX 4.40
- 52 Week Low
- AUTL $2.07
- PCRX $11.16
- 52 Week High
- AUTL $7.37
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- AUTL 41.40
- PCRX 77.75
- Support Level
- AUTL $2.07
- PCRX $25.06
- Resistance Level
- AUTL $2.26
- PCRX $27.10
- Average True Range (ATR)
- AUTL 0.12
- PCRX 1.45
- MACD
- AUTL 0.01
- PCRX 0.28
- Stochastic Oscillator
- AUTL 25.00
- PCRX 86.23
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.